Dupixent® (dupilumab) is the first biologic to significantly reduce itch and skin lesions in phase 3 trial for prurigo nodularis, demonstrating the role of type 2 inflammation in this disease

Dupixent ® (dupilumab) is the f irst b iologic to s ignificantly reduce i tch and s kin l esions in p hase 3 t rial for p rurigo n odularis, demonstrating the role of t ype 2 inflammation in this disease
REGN Ratings Summary
REGN Quant Ranking